238 related articles for article (PubMed ID: 11477342)
1. The effects of lipid-lowering agents on acute renal allograft rejection.
Kasiske BL; Heim-Duthoy KL; Singer GG; Watschinger B; Germain MJ; Bastani B
Transplantation; 2001 Jul; 72(2):223-7. PubMed ID: 11477342
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil.
Vergoulas G; Miserlis G; Solonaki F; Imvrios G; Gakis D; Papanikolaou V; Papagiannis A; Visvardis G; Takoudas D; Antoniadis A
Transpl Int; 2000; 13 Suppl 1():S64-7. PubMed ID: 11111964
[TBL] [Abstract][Full Text] [Related]
3. Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Ashraf R; Amir K; Shaikh AR
J Pak Med Assoc; 2005 Aug; 55(8):324-7. PubMed ID: 16164158
[TBL] [Abstract][Full Text] [Related]
4. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Mehra MR; Uber PA; Vivekananthan K; Solis S; Scott RL; Park MH; Milani RV; Lavie CJ
J Am Coll Cardiol; 2002 Nov; 40(9):1609-14. PubMed ID: 12427413
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J
Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327
[TBL] [Abstract][Full Text] [Related]
7. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Baigent C; Landray M; Leaper C; Altmann P; Armitage J; Baxter A; Cairns HS; Collins R; Foley RN; Frighi V; Kourellias K; Ratcliffe PJ; Rogerson M; Scoble JE; Tomson CR; Warwick G; Wheeler DC
Am J Kidney Dis; 2005 Mar; 45(3):473-84. PubMed ID: 15754269
[TBL] [Abstract][Full Text] [Related]
8. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
10. Lipid-lowering agents for nephrotic syndrome.
Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
[TBL] [Abstract][Full Text] [Related]
11. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Smit JW; Jansen GH; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial.
Holdaas H; Jardine AG; Wheeler DC; Brekke IB; Conlon PJ; Fellstrøm B; Hammad A; Holme I; Isoniemi H; Moore R; Rowe PA; Sweny P; Talbot DA; Wadstrøm J; Østraat Ø
Kidney Int; 2001 Nov; 60(5):1990-7. PubMed ID: 11703619
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of simvastatin for high-risk hypercholesterolemia.
Mölgaard J; Wärjerstam-Elf S; Olsson AG
Am J Cardiol; 1999 Apr; 83(7):1043-8. PubMed ID: 10190517
[TBL] [Abstract][Full Text] [Related]
14. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
Farnier M
Am J Cardiol; 1998 Aug; 82(4B):47J-51J. PubMed ID: 9737646
[TBL] [Abstract][Full Text] [Related]
15. 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
Bloomgarden ZT
Diabetes Care; 2005 Nov; 28(11):2795-802. PubMed ID: 16249560
[No Abstract] [Full Text] [Related]
16. [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Berioli S; Bentivoglio M; Conti R; Osanna RA; Savino K; Zollino L; Corea L
Cardiologia; 1990 Apr; 35(4):335-40. PubMed ID: 2245435
[TBL] [Abstract][Full Text] [Related]
17. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients.
Hanes DS; Nicholson PG; Raval DD; Hooper FL; Behrens MT; Weir MR
Am J Ther; 1997; 4(2-3):85-91. PubMed ID: 10423597
[TBL] [Abstract][Full Text] [Related]
18. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
Ichimaru N; Takahara S; Kokado Y; Wang JD; Hatori M; Kameoka H; Inoue T; Okuyama A
Atherosclerosis; 2001 Oct; 158(2):417-23. PubMed ID: 11583721
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
[TBL] [Abstract][Full Text] [Related]
20. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC
Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
